Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): A new seromarker for inflammatory bowel disease and associated disorders

Clinical and Experimental Immunology

Volumn 104, Issue 1, 1996, Pages 54-59

  Stoffel, M P ^a   Csernok, E ^a   Herzberg, C ^a   Johnston, T ^a   Carroll, S F ^b   Gross, W L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b XOMA Corporation   (United States)

Author keywords

anti neutrophil cytoplasmic antibodies (ANCA); bactericidal permeability increasing protein; inflammatory bowel disease

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; GRANULOCYTE ANTIBODY;

ARTICLE; CONTROLLED STUDY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0029882833     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-654.x     Document Type: Article

References (26)

1. Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Op Rheumatol 1995; 7:11-19.
2. Nölle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 1989; 111:28-40.
3. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1:425-9.
4. Ulmer M, Rautmann A, Gross WL. Immundiagnostic aspects of autoantibodies against myeloperoxidase. Clin Nephrol 1992; 37:161-8.
5. Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651-7.
6. Hauschild S, Schmitt W, Csernok E. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel disease. In: Gross WL, ed. ANCA associated vasculitides. New York: Plenum Press, 1993: 245-51.
7. Rump JA, Schölmerich J, Gross V et al. A new type of antineutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiol 1990; 181:407-13.
8. Halbwachs-Mecarelli L, Nusbaum P, Noel EH et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90:79-94.
9. Skogh T, Peen E. Lactoferrin, anti-lactoferrin antibodies and inflammatory disease. In: Gross WL, ed. ANCA associated vasculitides: immunological and clinical aspects. New York: Plenum Press, 1993:533-38.
10. Schmitt WH, Csernok E, Flesch BK, Hauschild S, Gross WL. Autoantibodies directed against lysozyme: a new target antigen for antineutrophil cytoplasmic antibodies (ANCA). In: Gross WL, ed. ANCA associated vasculitides. New York: Plenum Press, 1993:267-72.
11. Monk M, Mendelolf AI, Siegel CI, Lilienfeld A. An epidemiological study of ulcerative colitis and regional enteritis among adults in Baltimore. Hospital incidence and prevalence. Gastroenterology 1967;53:198-210.
12. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995; 99:49-56.
13. Bloch DA, Michel BA, Hunder GG et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthritis Rheum 1990; 33:1068-73.
14. Tedesco FH. Differential diagnosis of ulcerative colitis and Crohn's ileo-colitis and other specific inflammatory disease of the bowel. Med Clin North Am 1980; 64:1173-83.
15. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Eng J Med 1995; 332:924-33.
16. Wiik A. Development of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989;97:12-15.
17. Hagen EC, Andrassy K, Csernok E et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection: a report on the first phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1993; 159:1-16.
18. Theofan G, Horwitz AH, Williams RE et al. An amino-terminal fragment of human lipopolysaccharide binding protein retains lipid A binding but not CD14-stimulatory activity. J Immunol 1994; 152:3623-9.
19. Falk RJ, Becker M, Terrell JC, Jennette JC. Antigen specificity of P-ANCA and C-ANCA. The Third International Workshop on ANCA. Am J Kidney Dis 1991; 18:197 (Abstr.).
20. Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100:1385-91.
21. Saxon A, Shanahan F, Landers C et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86:202-10.
22. Mulder AHL, Broekroelofs J, Horst G et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 1994; 95:490-7.
23. Mayet WJ, Hermann E, Finsterwalder J et al. Antibodies to cathepsin G in Crohn's disease. Eur J Invest 1992; 22:427-33.
24. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus - prevalence, specificities, and clinical significance. Arthritis Rheum 1995; 38:633-7.
25. Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem 1989; 264:9505-9.
26. Kay RA. The potential role of superantigens in inflammatory bowel disease. Clin Exp Immunol 1995; 100:4-6.